66225-78-3

66225-78-3 structure

Name: Gly MCA
Chemical Name: 2-((4R)-4-((3R,5R,6S,7R,10R,13R)-3,6,7-Trihydroxy-10,13-Dimethylhexadecahydro-1H-Cyclopenta[A]Phenanthren-17-Yl)Pentanamido)Acetic Acid
CAS Number: 66225-78-3
Molecular Formula: C₂₆H₄₃NO₆
Molecular Weight: 465.62
Catalog: Signaling Pathways Metabolic Enzyme/Protease FXR
Create Date: 2018-07-10 21:14:58
Modify Date: 2024-01-02 10:45:51
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1].

Name	2-((4R)-4-((3R,5R,6S,7R,10R,13R)-3,6,7-Trihydroxy-10,13-Dimethylhexadecahydro-1H-Cyclopenta[A]Phenanthren-17-Yl)Pentanamido)Acetic Acid
Synonyms	Gly-β-MCA

Description	Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> FXR Research Areas >> Metabolic Disease
Target	FXR[1].
In Vitro	Gly-β-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor[1]. Gly-β-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH[1].
In Vivo	Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice[1]. Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation[1].
References	[1]. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.

Molecular Formula	C₂₆H₄₃NO₆
Molecular Weight	465.62